-
Mashup Score: 0Systemic mastocytosis presenting with episodic rigors - 7 month(s) ago
The clinical presentation of systemic mastocytosis (SM) is heterogeneous, but common signs and symptoms include rash, flushing, tachycardia, fatigue, musculoskeletal pain, hypotension, weight loss, and recurrent anaphylaxis.1 Herein, we report a unique case of a patient who presented with episodic, cold-induced rigors and was ultimately diagnosed with SM.
Source: www.jaci-inpractice.orgCategories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 0Tyrosine Kinase Inhibitors in Mastocytosis-[2023 SLIDES] - 7 month(s) ago
By: Allen Wilbanks Date: 09/27/2023 William Shomali, MD, is a respected expert in systemic mastocytosis, known for his collaborative work with Jason Gottlieb at Stanford University. In a recent presentation, he shared valuable insights on this complex condition. Dr. Shomali began by expressing gratitude for the invi…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🔬 @WilliamShomali, MD, Systemic Mastocytosis expert @StanfordHealth: 📋 Diagnosis 📈 Prognosis 💊 Treatment (incl. TKIs) 🧪 Ongoing research [Slides][Video] 👉 https://t.co/CjaV8GQAhi For the medical community! 🌟 @_MDEducation @_Ryan_fitzpatric #Mastocytosis https://t.co/LCBsUcs672
-
-
Mashup Score: 0Current and Emergent Therapies for Systemic Mastocytosis - 7 month(s) ago
The field of mastocytosis is witnessing a paradigm shift with precision medicine in the form of mutant KIT inhibitors.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Mastocytosis is organized into 2 broad types: cutaneous mastocytosis and systemic mastocytosis. This article further discusses these classifications based on a discussion at #SOHO23 | @pankitvachhani @MDAndersonNews https://t.co/iqYo7UMBpR
-
-
Mashup Score: 2Randomized controlled trial of omalizumab in treatment-resistant systemic and cutaneous mastocytosis (ROAM) - 9 month(s) ago
Mastocytosis is a rare clonal disorder of mast cells, manifestations of which are protean and can include anaphylaxis, urticaria/angioedema, malabsorption, and osteoporosis. Although there is no known cure, treatments include antimediator medications and cytoreductive therapy.1 More recent treatments include agents targeting the commonly associated mutations in the KIT receptor (CD117), but these can have significant adverse effects.2
Source: www.jaci-inpractice.orgCategories: Allergy-Immunology, Latest HeadlinesTweet-
In Current Issue! #Randomized #controlled #trial of #omalizumab in #treatment-resistant #systemic and #cutaneous #mastocytosis (ROAM) https://t.co/ATkPmRmjXS https://t.co/sb3L56EYIU
-
-
Mashup Score: 1FDA Approves Avapritinib for Indolent Systemic Mastocytosis - 11 month(s) ago
The FDA has approved avapritinib for adult patients with indolent systemic mastocytosis based on findings from the phase 2 PIONEER trial.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
BREAKING: The #FDA has approved #avapritinib for adult patients with indolent systemic #mastocytosis. https://t.co/ntro5Al3jL https://t.co/oQ07n6q98J
-
-
Mashup Score: 0European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives - 1 year(s) ago
In 2002, the European Competence Network on Mastocytosis (ECNM) was launched as a multidisciplinary collaborative initiative to increase the awareness and to improve diagnosis and management of patients with mast cell (MC) disorders. The ECNM consists of a net of specialized centers, expert physicians, and scientists who dedicate their work to MC diseases. One essential aim of the ECNM is to…
Categories: Allergy-Immunology, Latest HeadlinesTweet-
In Press! European Competence Network on #Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives https://t.co/hoQuj9kTHT
-
-
Mashup Score: 0
In another interview segment, Castells discussed the safety profile of avapritinib for indolent systemic mastocytosis, as well as future research.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
Mariana Castells, MD, PhD, spoke with @MDMagazine in another interview regarding her team’s findings on future areas of research & the safety profile of #avapritinib. View the interview here: https://t.co/N9oN0pT5J5 #allergy #mastocytosis
-
-
Mashup Score: 0Mariana Castells, MD, PhD: Trial Results for Avapritinib, Indolent Systemic Mastocytosis - 1 year(s) ago
In another interview segment, Castells went further into depth regarding the PIONEER trial results and regarding avapritinib’s effect on mastocytosis.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
Mariana Castells, MD, PhD, discussed the results of the PIONEER trial on #avapritinib for indolent systemic #mastocytosis and the results of her team’s research. Check out the interview here: https://t.co/OdmWJxRTVV #allergy #AAAAI23
-
-
Mashup Score: 0Reply to “MRGPRX2: A novel biomarker in mastocytosis?” - 1 year(s) ago
We read with interest the correspondence from Konantz and colleagues1 and are in complete agreement with their conclusion that the significance of Mas-related G protein–coupled receptor X2 (MRGPRX2) expression by mast cells in the skin of patients with mastocytosis remains of unknown significance and requires further study and insight. The observation that serum levels of MRGPX2 in patients with…
Categories: Allergy-Immunology, Latest HeadlinesTweet-
In Current Issue (FREE)! Reply to “ #MRGPRX2: A #novel #biomarker in #mastocytosis?” https://t.co/c7TgDNSdtV
-
-
Mashup Score: 1
Mastocytosis encompasses a heterogeneous group of diseases characterized by tissue accumulation of clonal mast cells (MC), which frequently includes bone involvement. Several cytokines have been shown to play a role in the pathogenesis of bone mass loss in systemic mastocytosis (SM), but their role in SM-associated osteosclerosis remains unknown.
Categories: Allergy-Immunology, Latest HeadlinesTweet-
In Press! #Bone and #cytokine #markers associated with bone #disease in #systemic #mastocytosis. https://t.co/9hGE9ZZTag
-
In Current Issue! #Systemic #mastocytosis presenting with #episodic #rigors https://t.co/CKtD9fraTv